We are live on ! Find out more
CRDF icon

Cardiff Oncology
CRDF

21 hedge funds and large institutions have $1.11M invested in Cardiff Oncology in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 3

22% more capital invested

Capital invested by funds: $915K → $1.11M (+$198K)

6.14% more ownership

Funds ownership: 1.25% → 7.39% (+6.1%)

19% less funds holding

Funds holding: 26 → 21 (-5)

50% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 10

Holders
21
Holders Change
-5
Holders Change %
-19.23%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
9
Reduced
3
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$164K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$73.4K
3
ARTA
A.R.T. Advisors
New York
+$37.1K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$33.7K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$8.4K

Top Sellers

1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$90K
2
EP
Elkhorn Partners
Nebraska
-$46K
3
DY
Dowling & Yahnke
California
-$43K
4
SNB
Security National Bank
Nebraska
-$22K
5
WS
Wedbush Securities
California
-$21K
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
26
Wealthspire Advisors (Maryland)
Maryland
– +$86 +24 New
1
2

CRDF Hedge Fund Activity: Q1 2019 in Review

21 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q1 2019, worth a combined $1.11M — up 22% from $915K a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of CRDF and 5 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 9 added.

The largest buyer was Renaissance Technologies, adding an estimated $164K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $90K sold.

  • 21 institutional investors held Cardiff Oncology (CRDF) as of Q1 2019, down from 26 in Q4 2018.
  • Funds reported $1.11M of Cardiff Oncology stock for Q1 2019, up 22% quarter-over-quarter.
  • 5 funds opened new Cardiff Oncology positions in Q1 2019 and 10 closed out, a net change of -5 holders.
  • The largest Cardiff Oncology buyer in Q1 2019 was Renaissance Technologies, an estimated $164K added.
  • The largest Cardiff Oncology seller in Q1 2019 was Susquehanna International Group, an estimated $90K sold.

Based on aggregated 13F filings for Q1 2019.